Invitae Hereditary Breast and Gyn Cancers Panel
Use
The Invitae Hereditary Breast and Gyn Cancers Panel analyzes genes associated with predisposition to adult-onset breast, ovarian, uterine, fallopian tube, and peritoneal cancers. This extensive panel testing helps evaluate several genes for a single clinical indication, potentially confirming diagnoses, predicting disease prognosis, facilitating early detection, assisting in family planning, and informing genetic counseling. It also supports clinical trial enrollment and focuses on heritable germline mutations, not somatic mutations in tumor tissue.
Special Instructions
This test is designed for germline mutations and will not detect somatic mutations. It uses whole blood in a purple-top EDTA tube as the preferred specimen, with saliva, buccal swab, and gDNA as alternates. The test offers customization by allowing genes to be toggled on or off, and it is New York approved.
Limitations
The test achieves >99% analytical sensitivity and specificity for single nucleotide variants and small indels but may have limitations in detecting large indels, structural rearrangements, or complex variants. Analysis excludes changes in promoters or non-coding regions unless specified. de novo variants affecting phasing or mapping, and single-exon copy number changes, may not be detected under certain conditions or sequence properties. Rarely, non-constitutional DNA from treatments like bone marrow transplants may affect results.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant